Advanced search
Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 7, 2022 - Issue 1
Submit an article Journal homepage
673
Views
0
CrossRef citations to date
0
Altmetric
Editorial

PD-L1 assessment in breast cancer immunotherapy: a critical overview

Angela Dalia Riccia Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaCorrespondence[email protected]
View further author information
,
Alessandro Rizzob Struttura Semplice Dipartimentale di Oncologia Medica per la presa in carico globale del paziente oncologico “Don Tonino Bello,” IRCCS Istituto Tumori“ Giovanni Paolo II, Bari, ItalyView further author information
,
Gennaro Palmiottib Struttura Semplice Dipartimentale di Oncologia Medica per la presa in carico globale del paziente oncologico “Don Tonino Bello,” IRCCS Istituto Tumori“ Giovanni Paolo II, Bari, ItalyView further author information
&
Giovanni Brandia Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaView further author information
Pages 58-59 | Received 18 Nov 2021, Accepted 23 Jun 2022, Published online: 30 Jun 2022

References

  • Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 Jan 23;6(1):8. PMID: 29357948; PMCID: PMC5778665.
  • Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2021 Jun;30:1–8. Epub ahead of print. PMID: 34167433
  • Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015 Sep;125(9):3335–3337. Epub 2015 Sep 1. PMID: 26325031; PMCID: PMC4588312
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
  • Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
  • Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. Faculty Rev 2019 Aug 2;8:1342 F100 PMID: 31448088; PMCID: PMC6681627
  • da Silva JL, Cardoso Nunes NC, Izetti P, et al. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020 Jan;145:102855. Epub 2019 Dec 20. PMID: 31927455
  • Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021 Mar;70(3):607–617. Epub 2020 Oct 5. PMID: 33015734
  • Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. Epub 2021 Feb 2. PMID: 33549983
  • Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048 investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23 Epub 2019 Nov 1;394(10212):1915–1928. Erratum in: Lancet. 2020 Jan 25;395(10220):272. Erratum in: Lancet. 2020 Feb 22;395(10224):564. Erratum in: Lancet. 2021 Jun 12;397(10291):2252. PMID: 31679945.
  • Badve SS, Penault-Llorca F, Reis-Filho JS, et al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from impassion130. J Natl Cancer Inst. 2021 Jul 20;113:390–399. Epub ahead of print. PMID: 34286340
  • Schmid P, Rugo HS, Adams S, et al. IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59. Epub 2019 Nov 27. PMID: 31786121
  • Rugo HS, Cortes J, Cescon DW, et al. KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol. 2021;32(suppl_5):S1283–S1346.
  • Schmid P, Cortes J, Dent R, et al. KEYNOTE-522 investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022 Feb 10;386(6):556–567. PMID: 35139274.
  • Rozenblit M, Huang R, Danziger N, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020 Nov;8(2):e001558. PMID: 33239417; PMCID: PMC7689582
  • Rugo HS, Loi S, Adams S, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J Natl Cancer Inst. 2021 Jun 7;113:1733–1743. Epub ahead of print. PMID: 34097070
  • Winer EP, Lipatov O, Im SA, et al. KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499–511. Epub 2021 Mar 4. PMID: 33676601
  • Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2021 Nov;25:1–7. Epub ahead of print. PMID: 34793275

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.